Protagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare Conference
The
A live audio webcast of the presentation may be accessed by visiting the Investors page of
About
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. Two of its clinical stage product candidates, PTG-100 and PTG-200, are oral targeted therapy drugs being developed for inflammatory bowel diseases (IBD). The alpha-4-beta-7 integrin antagonist peptide PTG-100 is currently in a Phase 2b clinical trial for moderate-to-severe ulcerative colitis, and the company's interleukin-23 receptor antagonist peptide PTG-200 is currently being studied in a Phase 1 clinical trial in healthy volunteers to support further development in Crohn's disease. Both alpha-4-beta-7 integrin and IL-12/23 pathway blockade are approaches that have been validated through
Protagonist is headquartered in Newark, California with pre-clinical and clinical staff in California, and discovery operations both in California and Brisbane, Queensland,
View original content with multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-28th-annual-oppenheimer-healthcare-conference-300611382.html
SOURCE
Joan Kureczka, Bioscribe, Inc., Tel: +1 415-821-2413, Mobile: +1 415-690-0210, email: Joan@bioscribe.com OR For Investors: The Trout Group, Marcy Nanus, 646-378-2927, mnanus@troutgroup.com